{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+Saline+%28Placebo%29+Infusion&page=8", "query": { "intervention": "Normal Saline (Placebo) Infusion", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 802, "total_pages": 81, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+Saline+%28Placebo%29+Infusion&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+Saline+%28Placebo%29+Infusion&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T05:24:57.403Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00990509", "title": "Albumin for Intracerebral Hemorrhage Intervention", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intracerebral Hemorrhage" ], "interventions": [ { "name": "Albumin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Brain MRI with and without contrast", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2009-09", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2014-08-29", "last_synced_at": "2026-10-13T05:24:57.403Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00990509" }, { "nct_id": "NCT00623363", "title": "Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Parkinson's Disease" ], "interventions": [ { "name": "piclozotan", "type": "DRUG" }, { "name": "0.9% sodium chloride (normal saline)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "40 Years to 85 Years" }, "enrollment_count": 27, "start_date": "2007-07-13", "completion_date": "2008-07-17", "has_results": true, "last_update_posted_date": "2021-03-11", "last_synced_at": "2026-10-13T05:24:57.403Z", "location_count": 5, "location_summary": "Fountain Valley, California • Tampa, Florida • Atlanta, Georgia + 2 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Brooklyn", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00623363" }, { "nct_id": "NCT00223704", "title": "Bradykinin Receptor Antagonism During Cardiopulmonary Bypass", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Cardiopulmonary Bypass", "Inflammation", "Fibrinolysis", "Surgery" ], "interventions": [ { "name": "HOE 140", "type": "DRUG" }, { "name": "Aminocaproic Acid", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 150, "start_date": "2006-05", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2013-11-25", "last_synced_at": "2026-10-13T05:24:57.403Z", "location_count": 2, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00223704" }, { "nct_id": "NCT07246863", "title": "Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Non-Squamous Non-Small Cell Lung Cancer", "Adult Solid Tumor" ], "interventions": [ { "name": "Visugromab RDE (recommended dose for expansion)", "type": "BIOLOGICAL" }, { "name": "Visugromab 6mg/kg", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Placebo Saline Infusion", "type": "OTHER" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "CatalYm GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 131, "start_date": "2025-10-07", "completion_date": "2031-10-01", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-13T05:24:57.403Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Los Angeles, California • Mineola, New York + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Mineola", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07246863" }, { "nct_id": "NCT00843193", "title": "Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "INTRAVENOUS GSK679586", "type": "DRUG" }, { "name": "INTRAVENOUS PLACEBO", "type": "DRUG" }, { "name": "FLUTICASONE PROPIONATE", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 198, "start_date": "2008-12-09", "completion_date": "2010-07-25", "has_results": true, "last_update_posted_date": "2017-12-12", "last_synced_at": "2026-10-13T05:24:57.403Z", "location_count": 6, "location_summary": "Medford, Oregon • Portland, Oregon • Pittsburgh, Pennsylvania + 3 more", "locations": [ { "city": "Medford", "state": "Oregon" }, { "city": "Portland", "state": "Oregon" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Orangeburg", "state": "South Carolina" }, { "city": "Boerne", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00843193" }, { "nct_id": "NCT02334059", "title": "Effect of Single Dose Ketamine and Magnesium on Postoperative Pain in Patients Undergoing Bariatric Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "Ketamine", "type": "DRUG" }, { "name": "Ketamine plus magnesium", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 108, "start_date": "2015-11", "completion_date": "2019-03-13", "has_results": true, "last_update_posted_date": "2020-06-01", "last_synced_at": "2026-10-13T05:24:57.403Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02334059" }, { "nct_id": "NCT01843790", "title": "A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Kidney Disease" ], "interventions": [ { "name": "GCS-100", "type": "DRUG" }, { "name": "Placebo, Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "La Jolla Pharmaceutical Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 120, "start_date": "2013-06", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2015-09-01", "last_synced_at": "2026-10-13T05:24:57.403Z", "location_count": 4, "location_summary": "Tempe, Arizona • La Mesa, California • Denver, Colorado + 1 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "La Mesa", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01843790" }, { "nct_id": "NCT03703297", "title": "Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 730, "start_date": "2018-09-27", "completion_date": "2026-10-23", "has_results": true, "last_update_posted_date": "2025-11-21", "last_synced_at": "2026-10-13T05:24:57.403Z", "location_count": 34, "location_summary": "Tucson, Arizona • Santa Rosa, California • New Haven, Connecticut + 30 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Santa Rosa", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Orange City", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03703297" }, { "nct_id": "NCT06769620", "title": "A First in Human Study of ORT247 in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Amyotrophic Lateral Sclerosis (ALS)" ], "interventions": [ { "name": "ORT247", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Orthogonal Neuroscience Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 44, "start_date": "2022-06-06", "completion_date": "2023-10-24", "has_results": false, "last_update_posted_date": "2025-01-15", "last_synced_at": "2026-10-13T05:24:57.403Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06769620" }, { "nct_id": "NCT02802592", "title": "EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cardiac Surgery-CABG", "Cardiac Valve Replacement" ], "interventions": [ { "name": "Epogen", "type": "DRUG" }, { "name": "Normal Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 4, "start_date": "2015-05", "completion_date": "2017-02-27", "has_results": true, "last_update_posted_date": "2019-02-26", "last_synced_at": "2026-10-13T05:24:57.403Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02802592" } ] }